|
Upcoming Catalysts Can Launch Geron Over $15 Per Share May 25, 2018 10:13 AM ET| 43 comments |About: Geron Corporation (GERN), JNJ Summary Major European June Conference Likely To Boost Worldwide Profile For Imetelstat. Accelerated Approval For Imetelstat Around End Of July Could Yield Peak Sales $2.5-$3.0 Billion In Myelofibrosis Alone. Continuation Decision By JNJ Can Come At Any Moment. Major upcoming catalysts can make Geron (GERN) stock soar This blog post is for my followers in advance of an upcoming article submission here on Seeking Alpha. Geron has major upcoming catalysts, I list them below with my price targets: - EHAC '18 Late Breaking Abstracts Available Online (June 1) - $6 - European Hematology Association Congress (June 14-17) - $8 - Accelerated Approval In Myelofibrosis (July 31) $16 - Continuation Decision by Johnson and Johnson (JNJ) (August 31) $20 - Accelerated Approval in Myelodysplastic Syndrome (September 30) $30 Major European June Conference Likely To Boost Worldwide Profile For Imetelstat Geron's upcoming major conference oral presentation includes several Janssen (JNJ) scientists as well as world renknown MDS expert Dr. Raza. They will be presenting updated MDS data from the iMerge trial which is showing efficacy more than twice as good as Revlimid; in some respects, it is transformational for patients with this disease. The global conference held in Sweden this year will likely be rocked by the major breakthrough Imetelstat will provide patients. The 20 patient extension for HMA and Revlimid naive patient data will be available at the meeting and may be presented. Imetelstat was granted Fast Track status late last year for MDS. Accelerated Approval For Imetelstat Around End Of July Could Yield Peak Sales $2.5-$3.0 Billion In Myelofibrosis Alone and exceed $6.0 Billion In MDS. Imetelstat exceeds all measures required for accelerated approval. The iMbark trial in MF completed in April and primary analysis is underway. Patients in the trial have no other options and thus no phase 3 would be required, nor would it be ethical. Median Overall Survival MOS already exceeds 2 years for patients that have, as CEO Scarlett mentioned 7-14 month expected survival. Furthermore, Imetelstat has shown disease reversal including complete responses to what the Mayo clinic espoused was "tantamount to a cure." Continuation Decision By JNJ Can Come At Any Moment. A continuation decision before the accelerated approvals can easily bring the stock to the high teens and around $30 post accelerated approval. At the annual shareholders meeting I attended, CEO Scarlett confirmed JNJ can do this at any time now. I attended the meeting as well as the informal discussion with execs after the meeting and I could tell you the sense that JNJ will move positively and quickly was palpable. Disclosure: I am/we are long GERN. Additional disclosure: This blog represents my opinion and is not considered investment advice. Please do your own due diligence. |
|
| aus der Diskussion: | Geron mit Hammernews!! |
| Autor (Datum des Eintrages): | Magnetfeldfredy (25.05.18 22:12:32) |
| Beitrag: | 2,683 von 3,090 (ID:57836387) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |